idea-006 · human · wrapped
Read this before anything else on the page. A low count here is usually a
statement about this repo's tooling rather than about the idea — a
unconfirmed reimbursement claim most often means the CMS cache file
is absent and nothing was searched, which is not evidence that a code
does not exist.
The packet a human reads. See docs/wrap-spec.md. This section says nothing about whether the idea is good — it says the file is finished enough to be read, and names what to do next. Filling it in advances no candidate and approves nothing.
The one-paragraph version. A cheaper second entrant into a new category of tinnitus treatment device. Tinnitus — persistent ringing with no external source — has no cure, and the treatments doctors are told to offer are counselling and hearing aids. In 2023 the FDA created a new device category for a different approach: playing sounds through headphones while delivering small timed electrical pulses to the body, so the brain re-learns to suppress the phantom sound. The device that created that category stimulates the tongue. This one would deliver the electrical half through a skin patch on the face or neck instead, be fitted remotely rather than in a clinic, and sell for less — aimed first at veterans, among whom tinnitus is unusually common.
What would have to be true, quoted from each deck's load-bearing condition:
Cheapest next test: Read the posted results of NCT03621735 — a completed University of Michigan randomized crossover trial of non-intraoral auditory-somatosensory bimodal stimulation, 100 participants actual, hasResults=true [claim 29: unconfirmed]. The file's own unresolved-claims analysis names it in exactly these terms: for the mechanism-transfer question "the settling artifacts are human: NCT03621735 ... is the first read, and an FDA Pre-Submission written response is what actually prices the NSE branch." A free registry record with outcome data already public, bearing on the branch point that decides whether the capital requirement is low single-digit millions or mid-eight figures. Selected from that gap analysis; this is a selection from it, not a new judgement, and not a view about the idea.
Where the evidence actually stands. 4 of 41 claims verified, 37 unconfirmed, none refuted. 7 of 9 factors carry a score in the Stage 2 triage table and 3 of 4 core factors do; the remaining rows carry named gaps rather than blanks.
All four verified claims are regulatory: the De Novo grant and its date [claim 1: verified], the QVN classification it created [claim 2: verified], and two facts about the adjacent tinnitus-masker regulation [claim 5: verified], [claim 6: verified]. They establish that the category exists and how FDA thinks about it. None of them touches the question the candidate itself calls its central risk — whether the mechanism survives moving off the tongue.
Thirteen claims were added by the research lane since 2026-08-24 and not one moved a tag, because they are literature, registry records and company press, none of which any connector here can verify. They nonetheless changed this packet substantially, and a Stage 6 reader should read the change as one finding rather than several: the category's evidence turns out to be good, and all of it belongs to somebody else.
The category is attractive. The treatments the 2014 AAO-HNSF guideline actually recommends underperform on their own measures: a Cochrane review of CBT (28 studies, n=2733) found a mean Tinnitus Handicap Inventory reduction of 5.65 points, below the review's own 7-point minimal clinically important difference [claim 35: unconfirmed], and a Cochrane review of sound therapy (8 studies, n=590) found no evidence that hearing aids, sound generators or combination devices beat waiting-list control, placebo or education-only [claim 36: unconfirmed]. That guideline contains no recommendation addressing bimodal neuromodulation at all [claim 39: unconfirmed].
The incumbent owns it. A 326-adult randomized double-blinded trial reported a Cohen's d of -0.87 to -0.92 on the THI at 12 weeks, P<.001 [claim 31: unconfirmed]. A 220-patient US real-world chart review reported a 91.5% responder rate, 95% CI 86.9%-94.5% [claim 33: unconfirmed]. A randomized settings trial reported 83.8% compliance [claim 32: unconfirmed]. And per company press materials the incumbent has held a VA Federal Supply Schedule 65 II A contract since 2024-06-17, extended beyond VA to Department of Defense, Bureau of Prisons, Indian Health Services and Public Health Service beneficiaries [claim 40: unconfirmed].
That last item answered the previous build's desirability load-bearing condition — whether the VA buys in this category — and answering it moved the question rather than closing it. The channel is open and occupied, so what this candidate now needs to know is whether a second, cheaper device gets ordered when the first is already on contract with a pivotal trial behind it. The file classifies that as evidence class 3, a stakeholder-future claim the adoption connector refuses, so no tooling will ever resolve it [claim 41: unconfirmed]. It needs VA audiologists asked.
Three cautions. The FSS award is sourced to a company press release, not a government record [claim 40: unconfirmed], and no connector here reads VA contracting — it should be confirmed against the VA National Acquisition Center's own listing before anything is built on it. The empirical case for the follower route is three years of silence in a classification created in March 2023 [claim 4: unconfirmed], which reads differently now that the incumbent spent those years compounding evidence and channel. And FTO is unexamined rather than clear [claim 28: unconfirmed] — never asked, on the rubric's one automatic-kill factor, against an incumbent whose patent position is the obvious blocking surface for a strategy that is explicitly to follow it.
| Intended use | For the treatment of adults aged 18 and older with chronic subjective tinnitus of moderate or greater severity, used at home on a prescribed daily schedule under the supervision of a licensed audiologist or physician, as an adjunct to tinnitus counselling. |
|---|---|
| Mechanism | Paired bimodal neuromodulation — timed acoustic stimulation delivered by headphones together with non-invasive transcutaneous electrical stimulation of a trigeminal/cervical afferent target, on a fixed daily treatment schedule, with remote (rather than in-clinic) fitting and adherence telemetry |
| Device class | # The launch route exists only because someone else's De Novo; Class II — 21 CFR 874.3410, product code QVN, "combined acoustic and electrical; external stimulation device for the relief of tinnitus" — 510(k) against the DEN210033; grantee as predicate. Launch designation. This regulation and code did not exist before; 2023; the whole candidate is a bet on a pathway a competitor's De Novo opened.; (Section number added post-Stage-3: the Generator originally left this route without a; CFR section, which left 874.3400 below as the only section in the frontmatter and; invited reading the launch and fallback routes as one regulation. They are two; different sections. 874.3410 is the Verifier's primary-source finding from; classification --product-code QVN; see claim 2.); Class II — 21 CFR 874.3400 ("tinnitus masker") — fallback route, live only for a; sound-only variant. Reachable, older, and much weaker commercially: a masker is; indicated to mask tinnitus, not to relieve it, so this route trades the therapeutic; claim for an easier submission. |
| Predicate or analog | Lenire (Neuromod Devices), granted via De Novo DEN210033 in March 2023 and,; per the Generator's web search, the device for which FDA created product; code QVN. Adjacent and older: sound-therapy tinnitus maskers under; 21 CFR 874.3400, and tinnitus modes embedded in conventional hearing aids. |
| Launch jurisdiction | US |
| Target | human |
| Factor | Score | What would settle it |
|---|---|---|
| Regulatory pathway | 2 | python3 -m connectors classification --product-code QVN — settles claim 2 and yields the CFR section. Then python3 -m connectors denovo "Lenire" for DEN210033 (claim 1), `python3 -m connectors regulation <section from classification>…the rest of this gap analysis--expect "acoustic and electrical", and python3 -m connectors regulation 874.3400 --expect "tinnitus masker" for claims 5-6. The NSE branch is priced by python3 -m connectors clearances --product-code QVN --since 3y then python3 -m connectors clearance-summary <K number> --expect-indication "chronic subjective tinnitus"` on each hit — whether FDA has ever cleared a non-intraoral electrode under QVN is the single most decision-relevant read in this file. |
| Reimbursement pathway | 1 | CPT is unverifiable by connector on purpose (python3 -m connectors cpt always returns unverifiable), so this factor cannot be closed from the repo alone. Runnable: python3 -m connectors hcpcs <candidate DME/L-code> and `python3 -m…the rest of this gap analysisconnectors coverage <code> --expect-stance covered once a candidate code is named; python3 -m connectors payment <code> --min-expected <net price>` to test whether any code pays above cost rather than merely existing. Human-attached primaries: the VA Federal Supply Schedule contract listing or VA prosthetics purchasing terms covering the predicate, and the predicate's published US patient price. A code that exists but pays below cost with no coverage policy would not move this row. |
| TAM | 2 | python3 -m connectors market "<TAM claim>" returns unverifiable by design — this factor cannot be closed by connector. Named primaries a human would have to attach: the VBA Annual Benefits Report PDF itself for claim 8 (no connector in…the rest of this gap analysisthis repo reads VA data), and a peer-reviewed NHANES-based prevalence analysis reporting chronic tinnitus by severity band for claim 10 — specifically a severity-stratified figure, since the widely quoted 25M "any tinnitus" numbers overstate the indicated population by a large multiple. For claim 11, the predicate's published US price list. Claim 12 stays an assumption until the first two resolve. |
| FTO / IP | — | Needs a patent number before any connector can run. Scout work item: USPTO Patent Public Search assignee query on "Neuromod Devices" for granted US families claiming paired acoustic-plus-somatosensory stimulation for tinnitus, plus the…the rest of this gap analysissame on the trigeminal/cervical stimulation art. Thenpython3 -m connectors patent <US patent number> per family for status, claims and expiry. A live enforceable claim reading on timed bimodal acoustic-plus-electrical stimulation with no workaround is an automatic kill under the rubric, so this row is worth resolving before spending on the others. |
| Moat / defensibility | 1 | Downstream of FTO: the patent search above is what determines whether there is a defensible position at all. Additionally python3 -m connectors clearances --product-code QVN --since 3y — a cleared follower shows the category is already…the rest of this gap analysiscontestable and that the Generator is not first; an empty result over three years is itself informative about barriers. |
| Mechanism & clinical risk | 2 | python3 -m connectors literature-detail <PMIDs from claim 13> for the pivotal trial and the 2025 chart review abstracts — effect size, comparator arm, durability. Then `python3 -m connectors literature "bimodal stimulation tinnitus…the rest of this gap analysistrigeminal" --since 5y and python3 -m connectors trials --condition tinnitus --intervention "bimodal stimulation" --since 5y, with trial-detail <NCT ID>` on any hit, to find whether any study exists at a non-intraoral electrode site. Note these are Stage 0 scans and return no confidence tag — they locate the evidence, they do not verify claim 14. |
| Capital intensity & time-to-revenue | 2 | Resolved indirectly by the Factor 1 reads: python3 -m connectors clearance-summary <K number> on any QVN clearance shows what evidence FDA actually accepted for that classification. The direct settling artifact is not a connector — it is…the rest of this gap analysisan FDA Pre-Submission (Q-Sub) written response on the electrode-site change, obtained by a human via a regulatory consultant. Until then this row stays a range, not an estimate. |
| Competitive intensity | 1 | python3 -m connectors clearances --product-code QVN --since 3y (claim 4 — who else is in), python3 -m connectors recalls --firm "Neuromod" --since 3y and python3 -m connectors recalls --product-code QVN --since 3y (incumbent field…the rest of this gap analysisperformance),python3 -m connectors trials --condition tinnitus --intervention "bimodal stimulation" --since 3y (who is running studies). All Stage 0 scans — pointers, not verification. |
| Strategic fit & portfolio balance | — | A Tier 3 human input, not a connector read: a stated portfolio thesis and current allocation from whoever owns capital allocation, supplied at Stage 6 shortlist review. |
All six wrap criteria are met.
Domain dossier: chronic-subjective-tinnitus-neuromodulation
Source file: knowledge-base/candidates/idea-006.md
Nothing on this page is a recommendation. Shortlist review, legal and clinical sign-off and capital allocation are human-only decisions, and no agent in this repo may make or simulate one. This is a compilation of what the candidate file says.